1. A pharmaceutical composition comprising: - a lipophilic beta-amyloid stilbene ligand and its acceptable salts, - ethanol, - a polyether, - ascorbic acid and sodium ascorbate. 2. The pharmaceutical composition of claim 1, wherein the lipophilic beta-amyloid stilbene ligand is methyl- [4 - ((F) -2- {4- [2- (2-propoxy-ethoxy) ethoxy] phenyl} vinyl ) -phenyl] -amine or a mixture of methyl- [4 - ((F) -2- {4- [2- (2-propoxy-ethoxy) ethoxy] phenyl} vinyl) phenyl] amine and methyl- [4 - ((18F) -2- {4- [2- (2-propoxy-ethoxy) ethoxy] phenyl} vinyl) phenyl] amine and its acceptable salts. 3. The pharmaceutical composition according to claim 1 or 2 and defined as follows: - from 0.03 GBq / ml to 5 GBq / ml methyl- [4 - ((18F) -2- {4- [2- (2-propoxy-ethoxy) - ethoxy] phenyl} vinyl) phenyl] amine, from 8% v / v up to 25% v / v ethanol, from 10% wt./about. up to 25% wt./about. polyethylene glycol, - from 0.01% to 3% wt./about. ascorbic acid and - from 0.01% to 20% wt./about. sodium ascorbate. 4. The pharmaceutical composition according to claim 3 and defined as follows: from 0.03 GBq / ml to 5 GBq / ml methyl- [4 g ((18F) -2- {4- [2- (2-propoxy-ethoxy) ethoxy] -phenyl} -vinyl) -phenyl] -amine, - 15% v / v ethanol, - 20% wt./about. PEG 400, 0.44% w / v ascorbic acid and - 2.88% wt./about. sodium ascorbate. 5. The pharmaceutical composition according to claim 1 or 2, defined as follows, from 0.01 μg / ml to 5 μg / ml methyl- [4 - ((F) -2- {4- [2- (2-propoxy-ethoxy) -ethoxy ] phenyl} vinyl) phenyl] amine or a mixture of methyl- [4 - ((F) -2- {4- [2- (2-propoxy-ethoxy) ethoxy] phenyl} vinyl) phenyl ] -amine and methyl- [4 - ((18F) -2- {4- [2- (2-propoxy-ethoxy) ethoxy] phenyl} vinyl) phenyl] amine and its acceptable salts, from 8% v / v up to 25% v / v ethanol, from 10% wt./about. up to 25% wt./about. polyethylene glycol, - from 0.01% to 3% wt./about. ascorbic acid and - from 0.01% to 20% wt./about. sodium ascorbate. 6. Pharmaceutical1. Фармацевтическая композиция, содержащая:- лип
